Last reviewed · How we verify
quetiapine fumarate vs risperidone
Quetiapine fumarate is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain, while risperidone is a similar atypical antipsychotic with higher D2 receptor affinity and additional alpha-adrenergic blocking activity.
Quetiapine fumarate is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain, while risperidone is a similar atypical antipsychotic with higher D2 receptor affinity and additional alpha-adrenergic blocking activity. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | quetiapine fumarate vs risperidone |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Both drugs are second-generation antipsychotics used to treat psychotic disorders and bipolar disorder. Quetiapine has a faster dissociation from D2 receptors and lower extrapyramidal side effect risk, while risperidone has greater potency at D2 receptors and may be more effective for certain psychotic symptoms. They differ in pharmacokinetics, side effect profiles, and clinical efficacy across different patient populations.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Major depressive disorder (adjunctive treatment)
Common side effects
- Sedation/somnolence
- Weight gain
- Dizziness
- Dry mouth
- Extrapyramidal symptoms
- Akathisia
- Hyperglycemia/metabolic effects
Key clinical trials
- A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard (PHASE1)
- A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia (PHASE1)
- New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia (PHASE3)
- Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI
- Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis (PHASE3)
- Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia (PHASE4)
- A Comparison of Seroquel vs. Risperidone in Schizophrenia (PHASE4)
- Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- quetiapine fumarate vs risperidone CI brief — competitive landscape report
- quetiapine fumarate vs risperidone updates RSS · CI watch RSS
- AstraZeneca portfolio CI